Abstract
Ethinylestradiol (EE) is a bioactive synthetic estrogen administered orally, currently categorized as a high potency and high added value drug (US $ 3,750.00 kg-1), being widely used in formulations of combined contraceptive drugs. It is known that even with the constant updating of good manufacturing practices (GMP), the production of EE is of high occupational risk and, to date, all of …